Video
Dr. Usmani on Subcutaneous Delivery of Daratumumab in Myeloma
Author(s):
Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses administering daratumumab (Darzalex) in patients with relapsed or refractory multiple myeloma.
Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses administering daratumumab (Darzalex) in patients with relapsed or refractory multiple myeloma.
This was an open-label, multicenter, dose-escalation phase Ib study to assess the subcutaneous delivery of daratumumab.
Intravenous infusion of daratumumab can take up to 8 hours, which is an inconvenience for many patients. In this study, subcutaneous delivery was tested as an attempt to cut down time spent administering the therapy.
Both the 1200 mg and 800 mg fixed doses were found to be tolerable, Usmani explains.
